247 related articles for article (PubMed ID: 28018602)
1. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model.
Gordy JT; Luo K; Zhang H; Biragyn A; Markham RB
J Immunother Cancer; 2016; 4():96. PubMed ID: 28018602
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
Gordy JT; Luo K; Francica B; Drake C; Markham RB
J Immunother; 2018 May; 41(4):181-189. PubMed ID: 29334492
[TBL] [Abstract][Full Text] [Related]
3. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.
Gordy JT; Luo K; Kapoor A; Kim ES; Ayeh SK; Karakousis PC; Markham RB
Cancer Immunol Immunother; 2020 Apr; 69(4):569-580. PubMed ID: 31980915
[TBL] [Abstract][Full Text] [Related]
4. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
5. IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
Gordy JT; Sandhu AK; Fessler K; Luo K; Kapoor AR; Ayeh SK; Hui Y; Schill C; Chen F; Wang T; Karanika S; Sunshine JC; Karakousis PC; Markham RB
Front Immunol; 2022; 13():1074644. PubMed ID: 36741387
[TBL] [Abstract][Full Text] [Related]
6. Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.
Fessler K; Gordy JT; Sandhu AK; Hui Y; Kapoor AR; Ayeh SK; Karanika S; Karakousis PC; Markham RB
Res Sq; 2023 Aug; ():. PubMed ID: 37645859
[TBL] [Abstract][Full Text] [Related]
7. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma.
Yazdani M; Gholizadeh Z; Nikpoor AR; Hatamipour M; Alani B; Nikzad H; Mohamadian Roshan N; Verdi J; Jaafari MR; Noureddini M; Badiee A
Vaccine; 2020 Jul; 38(35):5665-5677. PubMed ID: 32653275
[TBL] [Abstract][Full Text] [Related]
9. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.
Huang FY; Wang JY; Dai SZ; Lin YY; Sun Y; Zhang L; Lu Z; Cao R; Tan GH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759233
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model.
Nawrath M; Pavlovic J; Moelling K
J Mol Med (Berl); 2001 Apr; 79(2-3):133-42. PubMed ID: 11357937
[TBL] [Abstract][Full Text] [Related]
11. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
Kalariya M; Amiji MM
Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
[TBL] [Abstract][Full Text] [Related]
12. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.
Rakhmilevich AL; Imboden M; Hao Z; Macklin MD; Roberts T; Wright KM; Albertini MR; Yang NS; Sondel PM
Clin Cancer Res; 2001 Apr; 7(4):952-61. PubMed ID: 11309346
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
[TBL] [Abstract][Full Text] [Related]
15. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
16. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
17. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
18. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
19. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
[TBL] [Abstract][Full Text] [Related]
20. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine.
Zhao F; Zhang R; Wang J; Wu D; Pan M; Li M; Guo M; Dou J
Int Immunopharmacol; 2017 Nov; 52():238-244. PubMed ID: 28950176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]